What's in Evofem Inc.'s pipeline?

Evofem Inc. has 4 drugs in our index: 3 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Evofem Inc.'s portfolio?

Top competitors by shared drug class: , Baxter, Laboratoire Innotech International, Mission Pharma, Sanofi.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/evofem-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Evofem Inc. — Portfolio Competitive Intelligence Brief

Evofem Inc. pipeline: 3 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Area	First approval
Solosec	SECNIDAZOLE	marketed	Nitroimidazole Antimicrobial [EPC]	Infectious Disease	2017-01-01
Amphora	Amphora	marketed		Other
Conceptrol	Conceptrol	marketed		Other
EVO100	EVO100	phase 3	Spermicide	Contraception

Therapeutic area mix

Other · 2
Contraception · 1
Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 1 shared drug class
Baxter · 1 shared drug class
Laboratoire Innotech International · 1 shared drug class
Mission Pharma · 1 shared drug class
Sanofi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Evofem Inc.:

Cite this brief

Drug Landscape (2026). Evofem Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/evofem-inc. Accessed 2026-05-13.